LIQUAEMIN LOCK FLUSH (heparin sodium) by Aspen Surgical is protein, antithrombin iii, to induce a conformational change, which markedly enhances the serine protease activity of antithrombin ii, thereby inhibiting the activated coagulation factors involved in the closing sequence, particularly xa and iia. First approved in 1939.
Drug data last refreshed 19h ago · AI intelligence enriched 4w ago
LIQUAEMIN LOCK FLUSH is a heparin sodium injectable solution used to maintain the patency of intravenous catheters and prevent thrombotic complications in clinical settings. It works by enhancing antithrombin III activity to inhibit coagulation factors Xa and IIa, preventing clot formation without lysing existing clots. This is a legacy anticoagulant with over 80 years of clinical use.
As LOE approaches, expect commercial team contraction and shift toward generic partnership or divestiture strategies rather than brand growth investments.
protein, antithrombin III, to induce a conformational change, which markedly enhances the serine protease activity of Antithrombin II, thereby inhibiting the activated coagulation factors involved in the closing sequence, particularly Xa and IIa. Small amounts of heparin inhibit Factor Xa, and…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Study With Heparin Sodium in Subcutaneous Administration
Study With Heparin Sodium in Intravenous Administration
Full Dose Tenecteplase (TNK-tPA) Together With Heparin Sodium, Full Dose Tenecteplase With Enoxaparin, Half Dose Tenecteplase Together With Abciximab and Heparin Sodium in Patients With Acute Myocardial Infarction (AMI)
Worked on LIQUAEMIN LOCK FLUSH at Aspen Surgical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
This product represents a stable but declining career opportunity; roles are primarily focused on margin protection, generic transition planning, and hospital relationship management rather than growth. Working on LIQUAEMIN LOCK FLUSH suits professionals seeking operational expertise in mature-market management or those transitioning toward post-LOE portfolio roles.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo